Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 37%
Hold 26%
Sell 5%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated expanding operating margins, outperforming its targeted range, which bodes well for its overall profitability. The company anticipates an average annual sales growth of approximately 10%, driven by an increasing portfolio in structural heart therapies and supportive market conditions. Additionally, favorable clinical outcomes and an anticipated growth in TAVR procedure volumes are expected to enhance the company's financial performance, potentially leading to a higher trading multiple.

Bears say

Edwards Lifesciences faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include a potentially lower growth outlook for its transcatheter aortic valve replacement (TAVR) business and a lagging innovation pipeline for tricuspid and mitral valve products, which may fail to meet sales expectations. Additionally, external pressures from increased competition, a challenging global regulatory environment, and economic headwinds such as inflation and hospital staffing shortages may hinder the company's ability to expand its market share and achieve revenue growth targets.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.